We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current BIXT market cap is 14.62M. The company's latest EPS is USD -0.0296 and P/E is -3.38.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1.63M | -1.27M | -4.22M | -2.14M | -3.83M |
| Net Income | -1.86M | -2.48M | -4.03M | -2.46M | -4.28M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 220k | 326k | 119k | 371k | 138k |
| Total Liabilities | 1.02M | 2.27M | 3.28M | 3.66M | 3.25M |
| Total Equity | -799k | -1.94M | -3.16M | -3.29M | -3.11M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -431k | -1.1M | -1.7M | -1.81M | -775k |
| Investing | N/A | -10k | -37k | -32k | -44k |
| Financing | 564k | 981k | 1.77M | 2.06M | 550k |
| Market Cap | 14.62M |
| Price to Earnings Ratio | -3.38 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 500 |
| Price to Book Ratio | -4.65 |
| Dividend Yield | - |
| Shares Outstanding | 144.64M |
| Average Volume (1 week) | 82.64k |
| Average Volume (1 Month) | 159.64k |
| 52 Week Change | -80.19% |
| 52 Week High | 0.51 |
| 52 Week Low | 0.071 |
| Spread (Intraday) | 0 (4.31%) |
| Company Name | Bioxytran Inc (QB) |
| Address |
401 ryland st ste 200-a reno, nevada 89502 |
| Website | https://www.bioxytraninc.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
